ELECLAZINE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H16F3N3O3.ClH
Molecular Weight	451.826
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.FC(F)(F)OC1=CC=C(C=C1)C2=CC3=C(OCCN(CC4=NC=CC=N4)C3=O)C=C2

InChI

InChIKey=ZRYHNOXHGYUHFF-UHFFFAOYSA-N

InChI=1S/C21H16F3N3O3.ClH/c22-21(23,24)30-16-5-2-14(3-6-16)15-4-7-18-17(12-15)20(28)27(10-11-29-18)13-19-25-8-1-9-26-19;/h1-9,12H,10-11,13H2;1H

HIDE SMILES / InChI

Description
Sources: https://adisinsight.springer.com/drugs/800037785 | https://www.ncbi.nlm.nih.gov/pubmed/27690427

Eleclazine (formerly known as GS-6615) is a dihydrobenzoxazepinone selective cardiac late sodium current inhibitor. Gilead Sciences is developing eleclazine as an oral treatment for long QT syndrome, hypertrophic cardiomyopathy, ischaemic heart disease, and Ventricular arrhythmias.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium channel protein type V alpha subunit 49 Target ID: CHEMBL1980 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29017927	Blocker 537		0.97 µM [IC50]

PubMed

Title	Date	PubMed
Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists.	2005 Apr 1	15780621
Substituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction.	2006 Mar	16611213
Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold.	2006 Mar 15	16427279

Patents

Sample Use Guides

In Vivo Use Guide

Phase 3 clinical trial designed to determine the efficacy, safety, and tolerability of the late sodium current inhibitor eleclazine in shortening the corrected QT (QTcF) interval in subjects with type 3 Long QT Syndrome (LQT3). 41 subjects with genotype-confirmed LQT3 received a 48 mg oral loading dose of eleclazine followed by 12 weeks of treatment with 3 mg oral eleclazine once daily and then 12 weeks of treatment with 6 mg oral eleclazine once daily.

Route of Administration: Oral

Name

Type

Language

ELECLAZINE HYDROCHLORIDE

Common Name

English

1,4-BENZOXAZEPIN-5(2H)-ONE, 3,4-DIHYDRO-4-(2-PYRIMIDINYLMETHYL)-7-(4-(TRIFLUOROMETHOXY)PHENYL)-, HYDROCHLORIDE (1:1)

Systematic Name

English

Eleclazine hydrochloride [WHO-DD]

Common Name

English

Code System Code Type Description

PUBCHEM

90479986